PHIO PHARMACEUTICALS CORP. Operating Lease, Expense
PHIO PHARMACEUTICALS CORP. (PHIO) reported Operating Lease, Expense of $900 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-06
- PHIO PHARMACEUTICALS CORP. operating lease, expense for the quarter ending 2026-06-30 was $900.00, a 89.29% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. operating lease, expense for the quarter ending 2026-03-31 was $900.00, a 89.29% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. operating lease, expense for the quarter ending 2025-12-31 was $9.00K, a 76.92% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. operating lease, expense for the quarter ending 2025-09-30 was $9.00K, a 12.50% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. operating lease, expense for fiscal 2025 was $31.00K, a 46.55% decline from fiscal 2024.
- PHIO PHARMACEUTICALS CORP. operating lease, expense for fiscal 2024 was $58.00K.
- PHIO PHARMACEUTICALS CORP. operating lease, expense for fiscal 2018 was $120.00K, a 4.35% increase from fiscal 2017.
- PHIO PHARMACEUTICALS CORP. operating lease, expense for fiscal 2017 was $115.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $900.00 10-Q · filed 2026-08-06 | $1.80K 10-Q · filed 2026-08-06 | $10.80K derived: sum of 3 quarters · filed 2026-08-06 | $19.80K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $900.00 10-Q · filed 2026-05-07 | $9.90K derived: sum of 2 quarters · filed 2026-05-07 | $18.90K derived: sum of 3 quarters · filed 2026-05-07 | $27.30K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $18.00K derived: sum of 2 quarters · filed 2026-03-05 | $26.40K derived: sum of 3 quarters · filed 2026-08-06 | $31.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $9.00K 10-Q · filed 2025-11-13 | $17.40K derived: sum of 2 quarters · filed 2026-08-06 | $22.00K 10-Q · filed 2025-11-13 | $64.80K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $8.40K 10-Q · filed 2026-08-06 | $16.80K 10-Q · filed 2026-08-06 | $55.80K derived: sum of 3 quarters · filed 2026-08-06 | $63.80K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $8.40K 10-Q · filed 2026-05-07 | $47.40K derived: sum of 2 quarters · filed 2026-05-07 | $55.40K derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $47.00K derived: sum of 2 quarters · filed 2026-03-05 | $58.00K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $8.00K 10-Q · filed 2025-11-13 | $19.00K 10-Q · filed 2025-11-13 | ||
| 2019-09-30 | $33.00K 10-Q · filed 2019-11-12 | $66.00K derived: sum of 2 quarters · filed 2019-11-12 | $94.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $33.00K 10-Q · filed 2019-08-12 | $61.00K 10-Q · filed 2019-08-12 | ||
| 2019-03-31 | $28.00K 10-Q · filed 2019-05-14 | |||
| 2018-12-31 | $120.00K 10-K · filed 2019-03-27 | |||
| 2017-12-31 | $115.00K 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |